Chapter 3

Potential Role of Optogenetics for The Development of Novel Antidepressants

T. Chase Francis and Mary Kay Lobo


The need for novel antidepressants is growing with the rate of depression diagnoses. Until recently, systems level analyses of brain physiology have been largely unavailable or outcomes have been overgeneralized to large subsets of neurons in depression. Optogenetics, promoting the use of genetic tools to control light-activated proteins in cells, provides neuroscientists with the ability to specifically control distinct circuits and cell subtypes in order to determine their roles in depression symptomology. This technique affords control at the systems, cellular, and molecular levels. Defining the sub-circuits, mediating depression symptomology through optogenetic studies, can provide information on the brain circuits and cell subtypes to potentially target with electrical and pharmacological therapeutics and treat depression symptoms.

Total Pages: 77-98 (22)

Purchase Chapter  Book Details


.Frontiers in Anti-infective Drug Discovery.
.Frontiers in Drug Design and Discovery.
.In Silico and In vitro Approaches to Screen the Anti-TB Activity of Benzothiazole Analogs.
.Anti-Obesity Drug Discovery and Development.